Disentangling the relationship between tumor genetic programs and immune responsiveness.
Disentangling the relationship between tumor genetic programs and immune responsiveness. Curr Opin Immunol. 2016 Mar 8;39:150-158 Authors: Bedognetti D, Hendrickx W, Ceccarelli M, Miller LD, Seliger B Abstract Correlative studies in humans have demonstrated that an active immune microenvironment characterized by the presence of a T-helper 1 immune response typifies a tumor phenotype associated with better outcome and increased responsiveness to immune manipulation. This phenotype also signifies the counter activation of immune-regulatory mechanisms. Variables modulating the development of an effective anti-tumor immune response are increasingly scrutinized as potential therapeutic targets. Genetic alterations of cancer cells that functionally influence intratumoral immune response include mutational load, specific mutations of genes involved in oncogenic pathways and copy number aberrations involving chemokine and cytokine genes. Inhibiting oncogenic pathways that prevent the development of the immune-favorable cancer phenotype may complement modern immunotherapeutic approaches. PMID: 26967649 [PubMed - as supplied by publisher]
The American Congress of Rehabilitation Medicine (ACRM) offers an opportunity for members to be the guest editor of a Supplement to its journal, the Archives of Physical Medicine and Rehabilitation (Archives). The goal of the ACRM supplements is to publish high quality scientific manuscripts, which are thematically organized and of interest to ACRM members and to the general readership of the Archives. We are interested in proposals in all fields of rehabilitation, but especially those of interest to the ACRM membership as indicated by the existence of special interest and networking groups for brain injury, spinal cord in...
Healthy women age 75 and older may not benefit from continued breast cancer...Read more on AuntMinnie.comRelated Reading: Is breast screening beneficial for sickly older women? ACP pushes breast cancer screening start from 40 to 50 DBT screening mammography benefits women over 65 Screening mammography still good for older women Age, not density, predicts interval breast cancer result
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (phar...
ConclusionsThere is a rich traditional knowledge regarding the ethnomedicinal uses of Hypericum species in China. Through phytochemical and pharmacological studies, several medicinal Hypericum from China have yielded many bioactive phytochemicals, possessing antitumor, anti-inflammatory, antimicrobial, and neuroprotective properties. Hypericum species from China are potential sources of drugs to fight cancer and other chronic diseases. Remarkably, nearly half of Hypericum species in China have rarely been studied, and their ethnomedicinal potential have not been scientifically evaluated. Thus, in vitro mechanistic studies,...
ConclusionsEV ‐miR‐21 in pleural lavage fluid is important as a diagnostic and prognostic factor. Moreover, EV‐miR‐21 induces the MMT, which can form premetastatic niches of dissemination in the pleural cavity.
ConclusionsOral maintenance chemotherapy with S1 or capecitabine can improve OS in mNPC. Posttreatment EBV ‐DNA was not only an independent prognosis factor for mNPC but also can screen out beneficiaries of maintenance chemotherapy.
ConclusionThe delivery of a CCM ‐based, centralized tele‐rehabilitation intervention to patients with advanced stage cancer is highly cost‐effective. Clinicians and care teams working with this vulnerable population should consider incorporating such interventions into their patient care plans.
ConclusionsBiopathology findings from this study support the different prognosis of infantile RMS. New fusion ‐positive SRMS has a very good outcome which may allow more conservative treatment in the future.
ConclusionThe nomogram and Aggtrmmns scoring system can predict OS and CSS in kidney cancer patients effectively, which may help clinicians personalize prognostic assessments and clinical decisions.
ConclusionsOur study indicated that EMT might play a vital role in the immune invasion of CTCs by regulating the expression of ULBP1 on CTCs. These findings could provide potential strategies for targeting the immune evasion capacity of CTCs.